Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6ATAC36P (RNA, U6atac small nuclear 36, pseudogene) is classified as a pseudogene derived from small nuclear RNA (snRNA); specifically, it is related to the U6atac snRNA family, which functions in the minor spliceosome complex. Pseudogenes like RNU6ATAC36P are non-coding genomic elements that resemble functional genes but typically lack the ability to produce active RNA or protein products due to accumulated mutations or genomic rearrangements. Consequently, RNU6ATAC36P is not considered an active gene or a drug target, nor does it play a known direct role in disease biology. Its function, if any, is likely limited to potential minor regulatory or evolutionary genomic effects, as with some other pseudogenes[3][8][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear 36, pseudogene (RNU6ATAC36P).